ArticleAnnals of surgical oncology2026
Simultaneous Omission of Sentinel Lymph Node Biopsy and Radiation in Older Women with Early ER+ Breast Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-World Clinical, Enviro-Logistical and Economic Implications of Sentinel Lymph Node Biopsy Omission in Early Breast Cancer.Annals of surgical oncology · 2026Article
- Tumor biology, treatment patterns, and recurrence in breast cancer patients aged 70-79 vs ≥ 80 years: a large-scale registry analysis.Archives of gynecology and obstetrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionOncologic outcome data on women with neither SLNB nor radiation are limited. We evaluated recurrence and survival in older women with early stage, ER+/HER2 negative breast cancer who underwent lumpectomy without SLNB or radiation. PATIENTS AND
methodsWomen treated for breast cancer from 2014 to 2022 were identified in a local tumor registry. Inclusion criteria were women 65 years and older, tumor size ≤ 5 cm, ER+ > 10%, HER2- invasive breast cancers treated with lumpectomy without SLNB or radiation. The Kaplan-Meier method was used to estimate curves for mortality and recurrence.
resultsA total of 116 women met inclusion criteria. Median age at time of surgery was 76 (IQR: 72-80) years. The majority of patients were white (85%). Most patients had a T1 tumor (85%) and ductal histology (78%). In total, 107 patients (92%) initiated adjuvant endocrine therapy with median therapy duration of 4.2 years. Of the 116 patients, 7 developed recurrence (6.0%). Of the seven recurrences, all were initially locoregional: six in breast and one axillary. Three women with recurrence underwent mastectomy (5 year mastectomy-free survival 97.4%). DISCUSSION: Locoregional recurrence was rare at a median follow up of over 5 years with simultaneous omission of SLNB and radiation in older women with early stage ER+, HER2- breast tumors. Death from non cancer causes was more common, highlighting the competing risks in this population. These findings support the oncologic safety of this approach in well selected patients-older women with low risk tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.